Alexis Borisy - 17 Jul 2025 Form 4 Insider Report for Blueprint Medicines Corp (BPMC)

Role
Director
Signature
/s/ Melissa Masse, Attorney-in-Fact
Issuer symbol
BPMC
Transactions as of
17 Jul 2025
Net transactions value
$0
Form type
4
Filing time
21 Jul 2025, 19:46:35 UTC
Previous filing
30 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Borisy Alexis Director C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE /s/ Melissa Masse, Attorney-in-Fact 21 Jul 2025 0001319446

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BPMC Common Stock Disposed to Issuer -3,902 -5% 74,160 17 Jul 2025 Direct F1, F2, F3
transaction BPMC Common Stock Disposition pursuant to a tender of shares in a change of control transaction -74,160 -100% 0 17 Jul 2025 Direct F1, F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BPMC Stock Option (Right to Buy) Disposed to Issuer -7,500 -100% 0 17 Jul 2025 Common Stock 7,500 $69.79 Direct F1, F2, F5
transaction BPMC Stock Option (Right to Buy) Disposed to Issuer -4,875 -100% 0 17 Jul 2025 Common Stock 4,875 $96.77 Direct F1, F2, F5
transaction BPMC Stock Option (Right to Buy) Disposed to Issuer -4,500 -100% 0 17 Jul 2025 Common Stock 4,500 $76.24 Direct F1, F2, F5
transaction BPMC Stock Option (Right to Buy) Disposed to Issuer -4,500 -100% 0 17 Jul 2025 Common Stock 4,500 $87.13 Direct F1, F2, F5
transaction BPMC Stock Option (Right to Buy) Disposed to Issuer -5,300 -100% 0 17 Jul 2025 Common Stock 5,300 $50.64 Direct F1, F2, F5
transaction BPMC Stock Option (Right to Buy) Disposed to Issuer -5,300 -100% 0 17 Jul 2025 Common Stock 5,300 $63.66 Direct F1, F2, F5
transaction BPMC Stock Option (Right to Buy) Disposed to Issuer -4,570 -100% 0 17 Jul 2025 Common Stock 4,570 $106.14 Direct F1, F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Alexis Borisy is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").
F2 Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.
F3 Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit ("RSU"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration.
F4 Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Consideration.
F5 Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.